Gillian McGovern, Editor

The approval comes after the phase 3 clinical trials MVOR-1 (NCT05296629) and MVOR-2 (NCT05343455).

At weeks 16 and 24, approximately 57% and 60% of patients with moderate to severe atopic dermatitis, respectively, achieved at least 75% improvement in Eczema Area and Severity Index score.

Compared with a short-acting β agonist (SABA) alone, inhaled corticosteroids (ICS) with formoteral and ICS with a SABA were associated with better asthma control.

If approved, the combination regimen would be the first FDA-approved treatment for adults with recurrent KRAS mutant low-grade serous ovarian cancer (LGSOC).

If approved, the investigational intravenous gene therapy will be the first disease-modifying therapy for developmental and epileptic encephalopathy (DEE).

This model, which uses technology that discovers black holes, pulls from real data to evaluate cancer treatments, optimizing treatment choices for patients with different cancers.

The accelerated approval comes after 48-week major molecular response rate data.

The investigators found that the SRGAP2 and SYNGAP1 genes act together to control the speed of human synapse development, which has impacts on neurodevelopmental disease pathways.

Pregnancy rtes show similarity across the different glucagon-like peptide-1 (GLP-1) medications that were prescribed.

The investigators note that these findings are significant because bile duct cancer is a rare disease with limited treatments and low survival rates.

The authors note that exercise beyond 3 times per week was not associated with a lower risk of asthma, and more research is needed to confirm this finding.

Results demonstrating safety and efficacy in those with anemia in non-dialysis dependent chronic kidney disease and anemia in dialysis-dependent chronic kidney disease were presented at the 2024 American Society of Nephrology Kidney Week.

In postmenopausal women, the gel can reduce moderate to severe hot flashes as well as menopausal changes and symptoms.

NCCN recommends ribociclib as a preferred CDK4/6 inhibitor adjuvant therapy for patients with HR+/HER2- EBC in combination with an aromatase inhibitor.

Congenital muscular dystrophy type 1a is a severe, early-onset condition that currently has no treatment, but MDL-101 may serve as a 1-time, durable treatment option.

The FDA announces a Class II recall for the lot #220128, which were reported to contain the presence of nitrosamine.

Researchers discuss how interleukin-5 monoclonal antibodies are a promising approach for patients who have steroid-resistant asthma.

Despite self-reported improvements in cognitive function, neuropsychological tests showed little differences between 2 patient groups.

Cabotegravir long-acting when used for HIV pre-exposure prophylaxis (PrEP) showed adherence, effectiveness, and improvements in quality of life by those who received the injection.

Dispensing, communicating, and recording information may look different at each center.

Women are more likely to face burnout because they are often balancing both workload and family or home life responsibilities.

The implementation of accountable care organizations (ACOs) also worsened disparities in any emergency department or hospital use for Medicaid-insured children with asthma.

In a study, RK-33 demonstrated positive effects against the protein DDX3, which is key in the growth of cancer cells and spreading of disease.

Disruptions in the salience network function are shown to influence the severity of mild behavioral impairment (MBI) symptoms.

Awareness of uterine fibroids and uterine fibroid embolization can prevent unnecessary hysterectomies, especially in Black women, who are more likely to have uterine fibroids.

Research funding that aims to understand impacts of systemic racism on pediatric asthma should include plans to undo policies that maintain inequities created by systemic racism.

The clinical hold is a result of a reported case of motor neuropathy in a phase 2 trial participant.

Patients aged 7 years and older can now be treated for their cataplexy or excessive daytime sleepiness with the extended-release oral formulation.

This approval makes foscarbidopa/foslevodopa the first and only subcutaneous 24-hour infusion of levodopa-based therapy for adults with Parkinson disease.